Clinical trials are critical for developing new treatments, but the industry faces chronic delays. Around 70% of trials are delayed before they even begin, and nearly 60% face costly amendments along the way. For big pharma running hundreds of trials a year, the financial stakes are enormous. But the real cost is human – every delay slows down access to treatments that could save lives.
Biorce's AI-native platform, Jarvis, simplifies the process from end to end – optimising everything from patient recruitment to protocol design and trial site selection. By drawing insights from more than 530,000 clinical studies, Biorce helps trial teams make smarter decisions early, avoiding costly detours later.
Clinical trials are critical for developing new treatments, but the industry faces chronic delays. Around 70% of trials are delayed before they even begin, and nearly 60% face costly amendments along the way. For big pharma running hundreds of trials a year, the financial stakes are enormous. But the real cost is human – every delay slows down access to treatments that could save lives.
Biorce's AI-native platform, Jarvis, simplifies the process from end to end – optimising everything from patient recruitment to protocol design and trial site selection. By drawing insights from more than 530,000 clinical studies, Biorce helps trial teams make smarter decisions early, avoiding costly detours later.
Explore companies within the same category
